2024
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer
Ríos-Hoyo A, Cobain E, Huppert L, Beitsch P, Buchholz T, Esserman L, van 't Veer L, Rugo H, Pusztai L. Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer. Journal Of Clinical Oncology 2024, 42: 2632-2636. PMID: 38593393, DOI: 10.1200/jco.23.02614.Peer-Reviewed Original Research
2022
167P KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy
Masfarré L, Rocha P, Clavé S, Moliner L, Navarro-Gorro N, Ríos-Hoyo A, Sánchez I, Giner M, Corbera A, Taus A, Bellosillo B, Arriola E. 167P KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy. Annals Of Oncology 2022, 33: s109. DOI: 10.1016/j.annonc.2022.02.199.Peer-Reviewed Original Research